Understanding APC

Dr. S. Meyers Posts a Video About Intermittent vs. Continuous Hormone Therapy for Men with Prostate Cancer and Bone Metastasis

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not [...]

By Malecare|2020-02-04T10:37:34-05:00June 13th, 2012|Advanced Prostate Cancer, ASCO, Bone Metastases, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Metastases, Uncategorized, Understanding APC|0 Comments

From ASCO: Liver Metastases And Its Prognostic Significance In Men With Metastatic Prostate Cancer

According to data presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655) the presences of liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC). William Kevin Kelly, DO, Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson, and colleagues from the [...]

By Malecare|2017-10-19T10:51:06-04:00June 11th, 2012|Advanced Prostate Cancer, ASCO, biomarkers, Clinical Trials, Clinical Trials, General Information, Metastases, Uncategorized, Understanding APC|0 Comments

Towards A Biomarker To Predict Survival in Advanced Prostate Cancer

According to the results of a study published in the Journal of Clinical Oncology a bone scan index (BSI) can assess response to treatment and predict survival in metastatic hormone-refractory prostate cancer. Men who have castrate resistant or metastatic hormone-refractory prostate cancer that no longer responds to hormonal therapy and has spread to distant sites [...]

By Malecare|2017-10-19T10:51:06-04:00June 8th, 2012|Advanced Prostate Cancer, biomarkers, Bone Metastases, Bone Mineral Density, Metastases, On The Horizon, Prostate Ponderings, Research, Uncategorized, Understanding APC|0 Comments

My Current Personal Take on Intermittent Hormone Therapy for Prostate Cancer

On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy is not as good as continuous hormone therapy with regard to [...]

By Malecare|2017-10-19T10:51:06-04:00June 7th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Me, Uncategorized, Understanding APC|8 Comments

The Anti-Depressant Cymbalta Can Help Manage Peripheral Neuropathy From Chemotherapy

In a study presented at ASCO, researchers found that the drug duloxetine (Cymbalta) can help to treat peripheral neuropathy, a painful side effect of chemotherapy using taxanes. Taxotere, the chemotherapy drug used to treat castrate resistant, advanced prostate cancer is a taxane. Peripheral neuropathy occurs when nerves in the body's peripheral nervous system (outside the [...]

By Malecare|2012-06-06T08:53:56-04:00June 6th, 2012|Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, peripheral neuropathy, Uncategorized, Understanding APC|0 Comments

New Research Contradicts Prior Understanding – Intermittent Hormone Therapy for Prostate Cancer Inferior to Continuous Therapy

At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center. Dr. Hussain discussed the findings from the phase III clinical trial SWOG-9346, the largest such study to date [...]

By Malecare|2017-10-19T10:51:07-04:00June 4th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|1 Comment

At the AUA Meeting – Does Provenge Provide Better Survival Numbers?

The recent AUA meetings in Atlanta had a number of interesting abstracts presented that concern men with advanced prostate cancer. Some of the more interesting abstracts were look back analysis of sipuleucel-T (Provenge) done by consultants for Dendreon, the company who manufactures Provenge. They took the data from the al three of the phase III [...]

By Malecare|2017-10-19T10:51:08-04:00May 30th, 2012|Advanced Prostate Cancer, AUA, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Provenge, Uncategorized, Understanding APC, vaccines|0 Comments

On the Horizon – TOK-001 (Galeterone)

Tokai, a Cambridge, MA based Pharmaceutical company, just presented a promising set of Phase I data pointing to the early efficacy of its "triple whammy" pill for castration-resistant prostate cancer, TOK-001 or galeterone. In their phase 1 trial the PSA levels in about half of the 49 men in the dose-ranging study declined 30% or [...]

By Malecare|2022-02-28T12:41:12-05:00May 25th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Research, TOK-001 (Galeterone), Uncategorized, Understanding APC|1 Comment

Zytiga – When Should We Discontinue Using It?

I have had a number of recent conversations with men with advanced prostate cancer who have been taking Abiraterone Acetate (Zytiga). The question that comes up in regular conversation is about knowing when Zytiga has stopped working or when Zytiga should be discontinued. All the real guidance we have to answer this question comes from [...]

By Malecare|2017-10-19T10:51:08-04:00May 24th, 2012|abiraterone acetate, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|42 Comments

New Data Indicates That Provenge Works Best In Men With Lower PSA Scores

Today, May 16, 2012, Dendreon, the makers of Provenge, disclosed a new analysis of data of its pivotal 512-patient study of men with castrate resistant prostate cancer who received sipuleucel-T (Provenge). The new analysis separated the men in the study into four quartiles based on their prostate-specific antigen (PSA) scores. The initial design of the [...]

By Malecare|2021-02-17T11:03:37-05:00May 16th, 2012|Advanced Prostate Cancer, ASCO, Drugs & Treatments, Provenge, Research, Uncategorized, Understanding APC, vaccines|2 Comments